The Persistent Challenge of Developing Addiction Pharmacotherapies

Area of Science:

• Pharmacology
• Neuroscience
• Addiction Medicine

Background:

• Current FDA-approved medications effectively treat alcohol, nicotine, and opioid use disorders.
• Preclinical animal models have identified potential therapeutics for psychostimulant use disorder.

Purpose of the Study:

• Review the development of eight compounds for drug addiction treatment.
• Evaluate the utility of animal models in predicting clinical efficacy for addiction pharmacotherapeutics.
• Examine the failure of a promising cocaine therapeutic to inform predictive validity of animal models.

Main Methods:

• Review of pharmacological mechanisms of addiction treatments.
• Analysis of preclinical animal models in drug discovery for addiction.
• Case study of a failed clinical trial for a cocaine use disorder therapeutic.

Main Results:

• Successful development of FDA-approved therapies for alcohol, nicotine, and opioid use disorders.
• Numerous promising psychostimulant addiction medications identified in animal research have failed in clinical trials.
• A specific cocaine therapeutic candidate failed to demonstrate clinical efficacy.

Conclusions:

• Preclinical models show limitations in predicting clinical success for psychostimulant addiction treatments.
• Further refinement of animal models is needed to improve the translation of preclinical findings to clinical outcomes for cocaine use disorder.
• Challenges remain in developing effective pharmacotherapies for psychostimulant use disorders.